<DOC>
	<DOCNO>NCT01028950</DOCNO>
	<brief_summary>To evaluate safety efficacy oral dose YM150 prevention venous thromboembolism ( VTE ) patient acute medical illness .</brief_summary>
	<brief_title>YM150 Prevention Venous Thromboembolism Patients With Acute Medical Illness</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Patient hospitalize within 2 day study 1 basic VTE risk Complete bed rest require fist day hospitalization least 4 day hospitalization Written inform consent obtain Subject history deep vein thrombosis and/or pulmonary embolism Subject hemorrhagic disorder and/or coagulation disorder Subject clinically important bleeding occur within 90 day prior obtain inform consent Subject acute bacterial endocarditis Subject uncontrolled severe moderate hypertension , retinopathy , myocardial infarction stroke Subject receive anticoagulants/antiplatelet agent Subject body weight less 40 kg Major trauma , major surgery , eye , spinal cord and/or brain surgery within 90 day prior obtain inform consent , subject schedule surgery study period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>YM150</keyword>
	<keyword>Bleeding</keyword>
	<keyword>VTE</keyword>
	<keyword>FXa inhibitor</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>Venous thromboembolism</keyword>
</DOC>